Marc L Evans


Ontology type: schema:Person     


Person Info

NAME

Marc L

SURNAME

Evans

Publications in SciGraph latest 50 shown

  • 2022-03-29 Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently in DIABETES THERAPY
  • 2022-03-20 The Place and Value of Sodium-Glucose Cotransporter 2 Inhibitors in the Evolving Treatment Paradigm for Type 2 Diabetes Mellitus: A Narrative Review in DIABETES THERAPY
  • 2022-01-27 Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors in DIABETES THERAPY
  • 2022-01-19 Meeting the Challenge of Virtual Diabetes Care: A Consensus Viewpoint on the Positioning and Value of Oral Semaglutide in Routine Clinical Practice in DIABETES THERAPY
  • 2021-12-21 New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice in DRUGS
  • 2021-11-05 A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future Perspectives in ADVANCES IN THERAPY
  • 2021-10-04 The Value of Insulin Degludec in Frail Older Adults with Type 2 Diabetes in DIABETES THERAPY
  • 2021-06-23 Optimising the Heart Failure Treatment Pathway: The Role of SGLT2 Inhibitors in DRUGS
  • 2021-04-26 One Hundred Years of Insulin: Value Beyond Price in Type 2 Diabetes Mellitus in DIABETES THERAPY
  • 2021-01-11 Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review in ADVANCES IN THERAPY
  • 2021-01-08 Correction to: Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies in DIABETES THERAPY
  • 2020-11-14 Risk Prediction of the Diabetes Missing Million: Identifying Individuals at High Risk of Diabetes and Related Complications in DIABETES THERAPY
  • 2020-11-13 Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials in DIABETES THERAPY
  • 2020-09-29 SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes in DIABETES THERAPY
  • 2020-09-03 Semaglutide: Charting New Horizons in GLP-1 Analogue Outcome Studies in DIABETES THERAPY
  • 2020-08-27 Dapagliflozin for Heart Failure with Preserved Ejection Fraction: Will the DELIVER Study Deliver? in DIABETES THERAPY
  • 2020-07-24 Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials in DIABETES THERAPY
  • 2020-07-13 Diabetes and Novel Coronavirus Infection: Implications for Treatment in DIABETES THERAPY
  • 2020-05-18 What Next After Metformin in Type 2 Diabetes? Selecting the Right Drug for the Right Patient in DIABETES THERAPY
  • 2020-04-18 Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial in ADVANCES IN THERAPY
  • 2020-04-15 Drug Therapy in Obesity: A Review of Current and Emerging Treatments in DIABETES THERAPY
  • 2020-01-20 Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDegLira) in People with Type 2 Diabetes in DRUGS
  • 2019-12-31 Correction to: Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes in DIABETES THERAPY
  • 2019-12-20 Renal Outcomes in Type 2 Diabetes: A Review of Cardiovascular and Renal Outcome Trials in DIABETES THERAPY
  • 2019-12-07 Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes in DIABETES THERAPY
  • 2019-09-04 Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin in DIABETES THERAPY
  • 2019-08-13 What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer? in DIABETES THERAPY
  • 2019-07-18 Correction to: SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice in DIABETES THERAPY
  • 2019-07-09 SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice in DIABETES THERAPY
  • 2019-01-31 The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease in BMC NEPHROLOGY
  • 2019-01-02 A Summary of 2018 and What Lies Ahead for Diabetes Therapy in 2019 in DIABETES THERAPY
  • 2018-09-06 Living with Type 2 Diabetes: Patient Commentary in Response to the Paper ‘SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice’ in DIABETES THERAPY
  • 2018-08-22 Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink in BMC NEPHROLOGY
  • 2018-08-10 Cost-Effectiveness of Insulin Degludec vs. Insulin Glargine U100 in Type 1 and Type 2 Diabetes Mellitus in a UK Setting in DIABETES THERAPY
  • 2018-07-23 SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice in DIABETES THERAPY
  • 2017-11-13 Factors that may Account for Cardiovascular Risk Reduction with a Dipeptidyl Peptidase-4 Inhibitor, Vildagliptin, in Young Patients with Type 2 Diabetes Mellitus in DIABETES THERAPY
  • 2017-09-25 Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK in DIABETES THERAPY
  • 2017-05-11 Action on diabetic macular oedema: achieving optimal patient management in treating visual impairment due to diabetic eye disease in EYE
  • 2017-02-16 Cost-effectiveness of Insulin Degludec Versus Insulin Glargine in Adults with Type 1 and Type 2 Diabetes Mellitus in DIABETES THERAPY
  • 2016-08-23 Cost-Effectiveness of Insulin Degludec/Insulin Aspart Versus Biphasic Insulin Aspart in Patients with Type 2 Diabetes from a Danish Health-Care Perspective in DIABETES THERAPY
  • 2016-07-18 Practical Approaches to Diabetes Care: An Introduction in DIABETES THERAPY
  • 2015-10-07 Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy in DIABETES THERAPY
  • 2015-03-18 Is There Evidence of Any Safety Differences Among DPP-4 Inhibitors in the Treatment of People with Type 2 Diabetes Mellitus and Reduced GFR Due to Chronic Kidney Disease? in DIABETES THERAPY
  • 2014-08-21 Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials in ADVANCES IN THERAPY
  • 2014-07-15 Increased Risk of Severe Hypoglycemic Events with Increasing Frequency of Non-severe Hypoglycemic Events in Patients with Type 1 and Type 2 Diabetes in DIABETES THERAPY
  • 2013-06-03 Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries in HEALTH AND QUALITY OF LIFE OUTCOMES
  • 2013-01-08 Evaluation of Insulin Use and Value for Money in Type 2 Diabetes in the United Kingdom in DIABETES THERAPY
  • 2012-12-08 A Retrospective, Case-Note Survey of Type 2 Diabetes Patients Prescribed Incretin-Based Therapies in Clinical Practice in DIABETES THERAPY
  • 2012-02-29 Pioglitazone in Clinical Practice: Where Are We Now? in DIABETES THERAPY
  • 2011-05-26 Long-term effects of insulin glargine on the risk of breast cancer in DIABETOLOGIA
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "affiliation": [
          {
            "affiliation": {
              "id": "http://www.grid.ac/institutes/grid.273109.e", 
              "type": "Organization"
            }, 
            "isCurrent": true, 
            "type": "OrganizationRole"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.415598.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.47170.35", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.241103.5", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.416025.4", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.8155.9", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.4425.7", 
            "type": "Organization"
          }, 
          {
            "id": "http://www.grid.ac/institutes/grid.5600.3", 
            "type": "Organization"
          }
        ], 
        "familyName": "Evans", 
        "givenName": "Marc L", 
        "id": "sg:person.01167546340.80", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80"
        ], 
        "sdDataset": "persons", 
        "sdDatePublished": "2022-12-01T07:13", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/person/person_808.jsonl", 
        "type": "Person"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/person.01167546340.80'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/person.01167546340.80'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/person.01167546340.80'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/person.01167546340.80'


     

    This table displays all metadata directly associated to this object as RDF triples.

    30 TRIPLES      10 PREDICATES      18 URIs      7 LITERALS      2 BLANK NODES

    Subject Predicate Object
    1 sg:person.01167546340.80 schema:affiliation Na88766cff81e4038832a99d961f86a5b
    2 grid-institutes:grid.241103.5
    3 grid-institutes:grid.415598.4
    4 grid-institutes:grid.416025.4
    5 grid-institutes:grid.4425.7
    6 grid-institutes:grid.47170.35
    7 grid-institutes:grid.5600.3
    8 grid-institutes:grid.8155.9
    9 schema:familyName Evans
    10 schema:givenName Marc L
    11 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01167546340.80
    12 schema:sdDatePublished 2022-12-01T07:13
    13 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    14 schema:sdPublisher Na293552014c1448aa5b3102f670a7e37
    15 sgo:license sg:explorer/license/
    16 sgo:sdDataset persons
    17 rdf:type schema:Person
    18 Na293552014c1448aa5b3102f670a7e37 schema:name Springer Nature - SN SciGraph project
    19 rdf:type schema:Organization
    20 Na88766cff81e4038832a99d961f86a5b schema:affiliation grid-institutes:grid.273109.e
    21 sgo:isCurrent true
    22 rdf:type schema:OrganizationRole
    23 grid-institutes:grid.241103.5 schema:Organization
    24 grid-institutes:grid.273109.e schema:Organization
    25 grid-institutes:grid.415598.4 schema:Organization
    26 grid-institutes:grid.416025.4 schema:Organization
    27 grid-institutes:grid.4425.7 schema:Organization
    28 grid-institutes:grid.47170.35 schema:Organization
    29 grid-institutes:grid.5600.3 schema:Organization
    30 grid-institutes:grid.8155.9 schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...